ViGenCell, Inc. 308080

KRX · South Korea · Health Technology

KRW 5,810.00-40.00 (-0.68%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

ViGenCell, Inc. 308080

KRX · South Korea · Health Technology

KRW 5,810.00-40.00 (-0.68%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

+16.43% · 6MFull-screen chart

Open KRW 5,850.00High KRW 6,020.00Low KRW 5,700.00Close KRW 5,810.00Volume 44.23K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: KRW 5,850.00
Day range: KRW 5,700.00 – KRW 6,020.00
52-week range: KRW 3,070.00 – KRW 17,360.00
Volume: 44.23K
Market cap: KRW 118.08B
Avg. volume (1Y): 982.79K

Performance

1 week

+0.69%

1 month

-5.99%

3 months

+4.68%

6 months

+15.28%

Year to date

-44.56%

1 year

+60.94%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Biotechnology
Country: South Korea
Exchange: KRX
Shares outstanding: 20.50M
Employees: 43
ISIN: KR7308080001
Beta: 1.15

Technical view

Mixed

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceApr 21, 2026

ViGenCell's VT-EBV-N Selected for Oral Presentation at ASCO 2026

ViGenCell Inc. (KOSDAQ: 308080), a clinical-stage biotechnology company based in South Korea focused on advanced cell therapies, today announced that results from its Phase 2 clinical study of VT-EBV-N have been selected for an oral presentation at the ASCO Annual Meeting 2026.

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.